Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs

Journal of Medicinal Chemistry

Volumn 47, Issue 17, 2004, Pages 4142-4146

  Van Huijsduijnen, Rob Hooft ^a   Sauer, Wolfgang H B ^a   Bombrun, Agnes ^a   Swinnen, Dominique ^a  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 (OXALYLAMINO)THIOPHENECARBOXYLIC ACID; AMINOBENZOIC ACID DERIVATIVE; ANTIDIABETIC AGENT; AZOLIDINEDIONE; BISMALTOLATOVANADIUM; DIFLUOROPHOSPHONATE; DIFLUOROPHOSPHONATE PHENYLALANINE; ERTIPROTAFIB; HYDROXYPHENYLAZOLE; METFORMIN; OXALYLAMINOBENZOIC ACID; OXINDOLE; PIOGLITAZONE; PIPERIDINE DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; PYRIDAZINE; PYRIMIDOTRIAZINEPIPERIDINE; PYRROLE; ROSIGLITAZONE; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; COMPETITIVE INHIBITION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; INSULIN TREATMENT; MOUSE; NONHUMAN; SHORT SURVEY;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; OBESITY; PROTEIN-TYROSINE-PHOSPHATASE;

EID: 3843121119     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030629n     Document Type: Short Survey

References (39)

1. Andersen, J. N.; Mortensen, O. H.; Peters, G. H.; Drake, P. G.; Iversen, L. F.; et al. Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol. Cell. Biol. 2001, 21, 7117-7136.
2. Hooft van Huijsduijnen, R. Protein Tyrosine Phosphatases: Counting the Trees in the Forest. Gene 1998, 225, 1-8.
3. Wälchli, S.; Colinge, J.; Hooft van Huijsduijnen, R. MetaBlasts: Tracing protein tyrosine phosphatase gene family roots from man to Drosophila melanogaster and Caenorhabditis elegans genomes. Gene 2000, 253, 137-143.
4. Elchebly, M.; Payette, P.; Michaliszyn, E.; Cromlish, W.; Collins, S.; et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999, 283, 1544-1548.
5. Klaman, L. D.; Boss, O.; Peroni, O. D.; Kim, J. K.; Martino, J. L.; et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell. Biol. 2000, 20, 5479-5489.
6. Hooft van Huijsduijnen, R.; Wälchli, S.; Ibberson, M.; Harrenga, A. Protein tyrosine phosphatases as drug targets; PTP1B and beyond. Expert Opin. Ther. Targets 2002, 6, 637-647.
7. Espanel, X.; Wälchli, S.; Pescini Gobert, R.; El Alama, M.; Curchod, M.-L.; et al. Pulling Strings below the Surface: Hormone Receptor Signaling through Inhibition of Protein Tyrosine Phosphatases. Endocrine 2001, 15, 19-28.
8. Cheng, A.; Dube, N.; Gu, F.; Tremblay, M. L. Coordinated action of protein tyrosine phosphatases in insulin signal transduction. Eur. J. Biochem. 2002, 269, 1050-1059.
9. Wälchli, S.; Curchod, M.-L.; Pescini Gobert, R.; Arkinstall, S.; Hooft van Huijsduijnen, R. Identification of tyrosine phosphatases that dephosphorylate the insulin receptor: a brute-force approach based on "substrate-trapping" mutants. J. Biol. Chem. 2000, 275, 9792-9796.
10. Møller, N.; Iversen, L.; Andersen, H. S.; McCormack, J. G. Protein tyrosine phosphatases (PTPs) as drug targets: Inhibitors of PTP1B for the treatment of diabetes. Curr. Opin. Drug Discovery Dev. 2000, 3, 527-540.
11. Wang, J.; Yuen, V. G.; McNeill, J. H. Effect of vanadium on insulin sensitivity and appetite. Metabolism 2001, 50, 667-673.
12. Zabolotny, J. M.; Bence-Hanulec, K. K.; Stricker-Krongrad, A.; Haj, F.; Wang, Y.; et al. PTP1B Regulates Leptin Signal Transduction in Vivo. Dev. Cell 2002, 2, 489-495.
13. Cheng, A.; Uetani, N.; Simoncic, P. D.; Chaubey, V. P.; Lee-Loy, A.; et al. Attenuation of Leptin Action and Regulation of Obesity by Protein Tyrosine Phosphatase 1B. Dev. Cell 2002, 2, 497-503.
14. Shimizu, S.; Ugi, S.; Maegawa, H.; Egawa, K.; Nishio, Y.; et al. Protein-tyrosine phosphatase 1B as new activator for hepatic lipogenesis via sterol regulatory element-binding protein-1 gene expression. J. Biol. Chem. 2003, 278, 43095-43101.
15. Haj, F. G.; Markova, B.; Klaman, L. D.; Bohmer, F. D.; Neel, B. G. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. J. Biol. Chem. 2003, 278, 739-744.
16. Asante-Appiah, E.; Kennedy, B. P. Protein tyrosine phosphatases: the quest for negative regulators of insulin action. Am. J. Physiol. Endocrinol. Metab. 2003, 284, E663-E670.
17. Lembertas, A. V.; Perusse, L.; Chagnon, Y. C.; Fisler, J. S.; Warden, C. H.; et al. Identification of an obesity quantitative trait locus on mouse chromosome 2 and evidence of linkage to body fat and insulin on the human homologous region 20q. J. Clin. Invest. 1997, 100, 1240-1247.
18. Ghosh, S.; Watanabe, R. M.; Valle, T. T.; Hauser, E. R.; Magnuson, V. L.; et al. The Finland-United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study. I. An autosomal genome scan for genes that predispose to type 2 diabetes. Am. J. Hum. Genet. 2000, 67, 1174-1185.
19. Sell, S. M.; Reese, D. Insulin-inducible changes in the relative ratio of PTP1B splice variants. Mol. Genet. Metab. 1999, 66, 189-192.
20. Echwald, S. M.; Bach, H.; Vestergaard, H.; Richelsen, B.; Kristensen, K.; et al. A P387L variant in protein tyrosine phosphatase-1B (PTP-1B) is associated with type 2 diabetes and impaired serine phosphorylation of PTP-1B in vitro. Diabetes 2002, 51, 1-6.
21. Mok, A.; Cao, H.; Zinman, B.; Hanley, A. J.; Harris, S. B.; et al. A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose tolerance in Oji-Cree. J. Clin. Endocrinol. Metab. 2002, 87, 724-727.
22. Di Paola, R.; Frittitta, L.; Miscio, G.; Bozzali, M.; Baratta, R.; et al. A variation in 3′ UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am. J. Hum. Genet. 2002, 70, 806-812.
23. Tobin, J. F.; Tam, S. Recent advances in the development of small molecule inhibitors of PTP1B for the treatment of insulin resistance and type 2 diabetes. Curr. Opin. Drug Discovery Dev. 2002, 5, 500-512.
24. Guertin, K. R.; Setti, L.; Qi, L.; Dunsdon, R. M.; Dymock, B. W.; et al. Identification of a novel class of orally active Pyrimido-[5,4-3][1,2,4] triazine-5,7-diamine-Based Hypoglycemic Agent with Protein Tyrosine Phosphatase Inhibitory Activity. Bioorg. Med. Chem. Lett. 2003, 13, 2895-2898.
25. Liu, G.; Trevillyan, J. M. Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes. Curr. Opin. Invest. Drugs 2003, 3, 1608-1616.
26. Liu, G. Protein tyrosine phosphatase 1B inhibition: opportunities and challenges. Curr. Med. Chem. 2003, 10, 1407-1421.
27. Hooft van Huijsduijnen, R.; Bombrun, A.; Swinnen, D. Selecting Protein Tyrosine Phosphatases as Drug Targets. Drug Discovery Today 2002, 7, 1013-1019.
28. Evans, J. L.; Jallal, B. Protein tyrosine phosphatases: their role in insulin action and potential as drug targets. Expert Opin. Ther. Pat. 1999, 8, 139-160.
29. Blaskovich, M. A.; Kim, H. O. Recent discovery and development of protein tyrosine phosphatase inhibitors. Expert Opin. Ther. Pat. 2002, 12, 871-905.
30. Bombrun, A.; Gerber, P.; Church, D. Preparation of oxindole hydrazide modulators of protein tyrosine phosphatases (PTPs). W00337328 Al, 2003.
31. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25; 2001, 46, 3-26.
32. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25; 2001, 46, 3-26.
33. PTP-112 Drug Report. The Investigational Drug Database 2003. www.iddb3.com (April 9, 2003).
34. You-Ten, K. E.; Muise, E. S.; Itie, A.; Michaliszyn, E.; Wagner, J.; et al. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J. Exp. Med. 1997, 186, 683-693.
35. Zinker, B.; Xie, N.; Clampit, J.; Ngiyen, P.; Wilcox, D.; et al. Antidiabetic effects of protein tyrosine phosphatase 1B (PTP1B) antisense treatment in a rodent model of diabetes: Potential therapeutic benefit. Diabetes 2001, 50 (S2), 1378.
36. Zinker, B. A.; Rondinone, C. M.; Trevillyan, J. M.; Gum, R. J.; Clampit, J. E.; et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11357-11362.
37. ISIS-11371 Drug Report 2003. The Investigational Drug Database. www.iddb3.com (November 17, 2003).
38. Cheon, H. G.; Kim, S. M.; Yang, S. D.; Ha, J. D.; Choi, J. K. Discovery of a novel protein tyrosine phosphatase-1B inhibitor, KR61639: potential development as an antihyperglycemic agent. Eur. J. Pharmacol. 2004, 485, 333-339.
39. Tjernberg, A.; Hallen, D.; Schultz, J.; James, S.; Benkestock, K.; et al. Mechanism of action of pyridazine analogues on protein tyrosine phosphatase 1B (PTP1B). Bioorg. Med. Chem. Lett. 2004, 14, 891-895.